TWST, US90184D1000

Twist Bioscience stock gets fiscal 2027 growth outlook at Jefferies

Published on 11/22/2026 at 13:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Twist Bioscience stock gets fiscal 2027 sales guidance of $550 million to $560 million. Management said capacity, not demand, limits AI growth.

Growth Outlook Broadens

  • Twist expects fiscal 2027 revenue of $550 million to $560 million.
  • AI-enabled drug discovery revenue reached $59 million in fiscal 2026, with at least $100 million targeted for fiscal 2027.
  • The company plans $150 million of capital spending over two years to expand production capacity.
TWST, US90184D1000, Illustration mit AI erstellt.

Twist Bioscience used its Jefferies Global Healthcare Conference on Tuesday, November 17, 2026, to outline faster growth across AI-enabled drug discovery, diagnostics and protein synthesis. In a Investing.com transcript attributed to Reuters, management said fiscal 2027 revenue should reach $550 million to $560 million after fiscal 2026 revenue of $459 million.

AI Demand Meets Capacity Limits

Twist said AI-enabled drug discovery revenue rose to $59 million in fiscal 2026 from $21 million a year earlier. Management is targeting at least $100 million from the business in fiscal 2027 and said customer demand, rather than a lack of orders, is driving the need for additional production capacity.

The company said it achieved adjusted EBITDA break-even in the fourth quarter of fiscal 2026. Management described the fiscal 2027 outlook as a disciplined view based on demand that can already be confirmed, leaving additional potential in AI drug discovery, next-generation sequencing and minimal residual disease testing.

Investment Supports Expansion

Twist plans $150 million of capital spending over fiscal 2027 and fiscal 2028, including $75 million in fiscal 2027. The projects include additional DNA synthesis writers, automation in GeneLab facilities, protein capacity and more characterization equipment.

Management said the main execution challenge is matching capacity additions with demand. It expects AI-related growth to benefit from broader adoption by pharmaceutical companies and from customers moving toward more complex protein formats that require larger data sets.

Twist Bioscience at a Glance

  • Company: Twist Bioscience Corporation
  • Ticker: TWST
  • Primary listing: NASDAQ
  • ISIN: US90184D1000

The broader US equity market context is available through the S&P 500.

More news and analyses on Twist Bioscience stock

Disclaimer...
en | US90184D1000 | TWST | boerse | 70544403 | bgmi